Chlamydial urethral infection in male students in Chiang Mai: a screening test of urine deposits by enzyme immunoassay (EIA).

Adolescent males are considered to be an important genital chlamydial reservoir. However, there has been little information on urethral chlamydial infection in Thai adolescent males. About one fourth of males who are genital chlamydial reservoirs are asymptomatic. An appropriate means of defining the extent of chlamydial infection in adolescent males would be a non-invasive screening survey, instead of the conventional method of a deep swab cell culture, which is painful. The objectives of this study were to estimate the prevalence and to determine what factors should indicate the use of a screening test for urethral chlamydial infection in adolescent males residing in Chiang Mai. Chlamydial urethritis was detected by examining urine deposits for chlamydial antigen by enzyme immunoassay (EIA).

Lack of effect of oral contraceptive use on the pharmacokinetics of quinine.

The pharmacokinetics of quinine after a single 600 mg oral dose of quinine sulphate were studied in seven female subjects who used oral contraceptives and in seven age-matched female controls who did not. There were no significant differences (P greater than 0.05) in the maximum plasma concentration (Cmax) and the time of peak concentration (tmax) between the subjects who used oral contraceptives (Cmax = 5.3 +/- 1.0 (s.d.) mg l-1; tmax = 1.4 +/- 0.7 h) and the control subjects (Cmax = 5.6 +/- 0.9 mg l-1; tmax = 2.1 +/- 0.9 h). The mean elimination half-life of quinine in the oral contraceptives user group (12.5 +/- 1.9 h) was similar (P greater than 0.05) to that in the control group (11.8 +/- 2.7 h). The oral clearance of quinine in the oral contraceptive user group was 0.133 +/- 0.055 l h-1 kg-1 (range 0.073-0.233) and was not significantly different (P greater than 0.05) from that observed in the control group (0.125 +/- 0.025 l h-1 kg-1, range 0.075-0.148).

A study of adrenal corticol function and its reserve activity in long-acting injectable contraceptive users.

Adrenal function and its reserve capacity were studied in eighteen healthy non-lactating women who received depot-medroxyprogesterone acetate (DMPA: 9 subjects) and norethisterone enanthate (NET-EN: 9 subjects) as long-acting injectable contraceptives. Methodological assessments included: (i) morning fasting concentration of serum cortisol; (ii) diurnal variation of adrenal corticol activity as evidenced by cortisol concentration in serum samples taken at 0700 and 1600 hours; (iii) urinary free cortisol excretion; and (iv) cortisol response to insulin-induced hypoglycaemia. None of these assessments was significantly altered by contraceptive administration. This finding indicates that the subject's ability to release cortisol in response to a stressful situation, as well as to normal day-to-day activity, was not impaired by these contraceptive steroids.

PIP: Adrenal cortical function and its reserve capacity were studied in 9 women who received depot medroxyprogesterone acetate (DMPA) and in 9 women who received norethisterone enanthate (NET-EN) as long acting injectable contraceptives. Adrenal function was assessed by means of morning fasting concentration of serum cortisol, diurnal variation of adrenal corticol activity, and measurement of free urinary cortisol, and cortisol release in response to insulin-induced hypoglycemia. These assessments were made both prior to and at intervals after the initiation of contraceptive treatment. Data were combined and presented in 4 blocks: before treatment; 30 days after 1st injection; during treatment (data from 3rd, 4th, and 5th assessments); and after treatment (6th assessment made 6 months after the last injection). Neither the fasting concentration nor the circadian rhythm of cortisol were significantly altered by the use of either form of gestagens, not even when subjects were exposed to a relatively high level of these steroids during the first 30 days of their injection. It seems likely that the slight but insignificant decrease in the mean levels of cortisol following the introduction of gestagen injectable contraceptives is related primarily to reduction of the plasma binding protein. The mean level of free cortisolin 24-hour urine collections remained unchanged in both groups of subjects, confirming that adrenal function remained essentially unchanged in injectable contraceptive users.

Serum prolactin and cortisol levels after suckling for varying periods of time and the effect of a nipple shield.

Plasma prolactin and cortisol levels were measured in mothers breast feeding with or without the use of a thin latex nipple shield, and in mothers wearing a nipple shield but who were not nursing. Suckling duration and milk transfer were also recorded. Suckling duration ranged between 6 and 31 min, being significantly correlated with prolactin levels 40 to 120 min after the feed started. At the latter time, baseline prolactin level and time spent nursing accounted together for most of the variance in prolactin levels: R2 was 0.79 and 0.82 at 90 min and 120 min respectively. Prolactin was released as usual when the shield was in place: levels were not significantly different from levels without the shield. Suckling duration was also unaffected by the shield, but milk transfer was significantly reduced. Cortisol was not released by using the shield, and the shield alone (without suckling) did not release prolactin. The thin latex nipple shield has therefore no untoward effect on the release of these hormones during nursing.